K
Konstanze Döhner
Researcher at University of Ulm
Publications - 416
Citations - 38559
Konstanze Döhner is an academic researcher from University of Ulm. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 84, co-authored 371 publications receiving 33217 citations.
Papers
More filters
Journal ArticleDOI
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Hartmut Döhner,Stephan Stilgenbauer,Axel Benner,Elke Leupolt,Alexander Kröber,Lars Bullinger,Konstanze Döhner,Martin Bentz,Peter Lichter +8 more
TL;DR: Genomic aberrations in chronic lymphocytic leukemia are important independent predictors of disease progression and survival and have implications for the design of risk-adapted treatment strategies.
Journal ArticleDOI
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Ross L. Levine,Ross L. Levine,Martha Wadleigh,Jan Cools,Benjamin L. Ebert,Benjamin L. Ebert,Gerlinde Wernig,Brian J. P. Huntly,Titus J. Boggon,Iwona Wlodarska,Jennifer J. Clark,Sandra A. Moore,Jennifer Adelsperger,Sumin Koo,Jeffrey C. Lee,Stacey Gabriel,Thomas Mercher,Alan D. D'Andrea,Stefan Fröhling,Konstanze Döhner,Peter Marynen,Peter Vandenberghe,Ruben A. Mesa,Ayalew Tefferi,James D. Griffin,Michael J. Eck,William R. Sellers,William R. Sellers,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Todd R. Golub,Todd R. Golub,Stephanie J. Lee,D. Gary Gilliland,D. Gary Gilliland,D. Gary Gilliland +36 more
TL;DR: High-throughput DNA resequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations.
Journal ArticleDOI
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil,Moritz Gerstung,Lars Bullinger,Verena I. Gaidzik,Peter Paschka,Nicola D. Roberts,Nicola E. Potter,Michael Heuser,Felicitas Thol,Niccolo Bolli,Gunes Gundem,Peter Van Loo,Inigo Martincorena,Peter Ganly,Laura Mudie,Stuart McLaren,Sarah O’Meara,Keiran Raine,David R. Jones,Jon W. Teague,Adam Butler,Mel Greaves,Arnold Ganser,Konstanze Döhner,Richard F. Schlenk,Hartmut Döhner,Peter J. Campbell +26 more
TL;DR: The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification.
Journal ArticleDOI
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Richard F. Schlenk,Konstanze Döhner,Jürgen Krauter,Stefan Fröhling,Andrea Corbacioglu,Lars Bullinger,Marianne Habdank,Daniela Späth,Michael Morgan,Axel Benner,Brigitte Schlegelberger,Gerhard Heil,Arnold Ganser,Hartmut Döhner +13 more
TL;DR: Genotypes defined by the mutational status of NPM1, FLT3, CEBPA, MLL, and MLL are associated with the outcome of treatment for patients with cytogenetically normal AML.
Journal ArticleDOI
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Richard Stone,Sumithra J. Mandrekar,Ben L. Sanford,Kristina Laumann,Susan Geyer,Clara D. Bloomfield,Christian Thiede,Thomas W. Prior,Konstanze Döhner,Guido Marcucci,Francesco Lo-Coco,Rebecca B. Klisovic,Andrew H. Wei,Jorge Sierra,Miguel A. Sanz,Joseph Brandwein,Theo de Witte,Dietger Niederwieser,Frederick R. Appelbaum,Bruno C. Medeiros,Martin S. Tallman,Jürgen Krauter,Richard F. Schlenk,Arnold Ganser,Hubert Serve,Gerhard Ehninger,Sergio Amadori,Richard A. Larson,Hartmut Döhner +28 more
TL;DR: The addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy significantly prolonged overall and event‐free survival among patients with AML and a FLT3 mutation.